SLC5A2 and chronic kidney disease: Landmark clinical trials such as DAPA-CKD, CREDENCE, and EMPA-KIDNEY provide solid scientific evidence supporting the use of SGLT-2 inhibitors in non-diabetic CKD patients, confirming their broad clinical benefits and excellent safety profile (9, 10).